Introgen Therapeutics, Inc. (fka INGNQ)

[poorgradstudent]

>1.What gives with the NDA since they published this data 8 months
ago?<

It's my understanding that the company was advised to let the survival data from ASCO mature out to another year. So they'll have some rather sturdy survival data at the time of sBLA submission.

>2. Since the trial compares with radiotherapy and not other drugs
such as MTX or FU5 how can we glean from this any useful comparison to the T301 trial?<

It is hard to make a stringent comparison when different drugs are being tested. Both IMCL and INGN would have to be rather comprehensive in their data release so that investors can decide whether a comparison is valid.

>3. Does IMCL have another PIII I havent found<

I don't follow imcl all that closely. To my knowledge, there is not another trial but I could certainly be wrong.